Abstract
Albuterol has been used for more than 40 years to treat acute asthma exacerbations as a racemic mixture of isomers: the active form, (R)-albuterol, or levalbuterol, and (S)-albuterol, classically considered inert. The single-isomer formulation, levalbuterol, has been synthesized recently and used therapeutically when the racemate is deemed less desirable. Basic investigations indicate that racemic albuterol and levalbuterol can produce effects that favor asthma remediation, including corticosteroid amplification and reduction of inflammatory mediators; in contrast, (S)-albuterol produces opposite effects. With inhalation of racemic albuterol, circulating (S)-albuterol persists 12 times longer than levalbuterol, suggesting potential for paradoxical effects observed clinically. Although mainly consistent with basic findings, clinical studies suggest no overwhelming superiority of levalbuterol over racemic albuterol; however, levalbuterol’s effects may be greatest in moderate to severe asthma patients, especially with racemic albuterol overuse. Recent adoption of the hydrofluoroalkane formulation has narrowed the cost gap between levalbuterol and racemic albuterol metered-dose inhalers, but it remains for the nebulized formulations. Thus, physician selection of these drugs has remained dependent on experience, pharmaceutical knowledge, and established prescribing habits combined with cost factors, formulary structures, and availability, such that racemic albuterol is still used significantly compared with levalbuterol to treat acute asthma exacerbations.
Similar content being viewed by others
References and Recommended Reading
Busse W, Banks-Schlegel S, Noel P, et al.: Future research directions in asthma: an NHLBI Working Group report. Am J Respir Crit Care Med 2004, 170:683–690.
Fuhlbrigge AL, Adams RJ, Guilbert TW, et al.: The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med 2002, 166:1044–1049.
Gilberg K, Laouri M, Wade S, Isonaka S: Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression, and CHF. J Manag Care Pharm 2003, 9:232–237.
Reed S, Diggle S, Cushley MJ, et al.: Assessment and management of asthma in an accident and emergency department. Thorax 1985, 40:897–902.
Penn RB, Frielle T, McCullough JR, et al.: Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 1996, 14:37–45.
Cockcroft DW, McParland CP, Britto SA, et al.: Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993, 342:833–837.
Spitzer WO, Suissa S, Ernst P, et al.: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992, 326:501–506.
Abramson MJ, Bailey MJ, Couper FJ, et al.: Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001, 163:12–18.
Nowak RM, Emerman CL, Schaefer K, et al.: Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004, 22:29–36.
Boulton DW, Fawcett JP: Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol 1996, 41:35–40.
Boulton DW, Fawcett JP: The pharmacokinetics of levosalbutamol: what are the clinical implications? Clin Pharmacokinet 2001, 40:23–40.
Morgan DJ, Paull JD, Richmond BH, et al.: Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986, 22:587–593.
Gumbhir-Shah K, Kellerman DJ, DeGraw S, et al.: Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol 1998, 38:1096–1106.
Naidu Sjosward K, Josefsson M, Ahlner J, et al.: Metabolism of salbutamol differs between asthmatic patients and healthy volunteers. Pharmacol Toxicol 2003, 92:27–32.
Eaton EA, Walle UK, Wilson HM, et al.: Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol 1996, 41:201–206.
Lipworth BJ, Clark DJ, Koch P, Arbeeny C: Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997, 52:849–852.
Gumbhir-Shah K, Kellerman DJ, DeGraw S, et al.: Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther 1999, 12:353–362.
Dhand R, Goode M, Reid R, et al.: Preferential pulmonary retention of (S)-albuterol after inhalation of racemic al buterol. Am J Respir Crit Care Med 1999, 160:1136–1141.
Hartley D, Middlemiss D: Absolute configuration of the optical isomers of salbutamol. J Med Chem 1971, 14:995–996.
Page CP, Morley J: Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol 1999, 104:S31–S41.
Cullum VA, Farmer JB, Jack D, Levy GP: Salbutamol: a new, selective betaadrenoceptive receptor stimulant. Br J Pharmacol 1969, 35:141–151.
Yamaguchi H, McCullough JR: S-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol 1996, 14:47–55.
Zhang XY, Zhu FX, Olszewski MA, Robinson NE: Effects of enantiomers of beta 2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol 1998, 274:L32–L38.
Johansson F, Rydberg I, Aberg G, Andersson RG: Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol 1996, 14:57–64.
Delmotte P, Sanderson MJ: Effects of albuterol isomers on the contraction and Ca2+ signaling of small airways in mouse lung slices. Am J Respir Cell Mol Biol 2008, 38:524–531.
Mitra S, Ugur M, Ugur O, et al.: (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol 1998, 53:347–354.
Mazzoni L, Naef R, Chapman ID, Morley J: Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics. Pulm Pharmacol 1994, 7:367–376.
Keir S, Page C, Spina D: Bronchial hyperresponsiveness induced by chronic treatment with albuterol: role of sensory nerves. J Allergy Clin Immunol 2002, 110:388–394.
Vargaftig BB: Modifications of experimental bronchopulmonary hyperresponsiveness. Am J Respir Crit Care Med 1997, 156:S97–S102.
Henderson WR Jr, Banerjee ER, Chi EY: Differential effects of (S)- and (R)-enantiomers of albuterol in a mouse asthma model. J Allergy Clin Immunol 2005, 116:332–340.
Agrawal DK, Ariyarathna K, Kelbe PW: (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004, 113:503–510.
Templeton AG, Chapman ID, Chilvers ER, et al.: Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther 1998, 11:1–6.
Lazaar AL, Amrani Y, Hsu J, et al.: CD40-mediated signal transduction in human airway smooth muscle. J Immunol 1998, 161:3120–3127.
Farmer P, Pugin J: Beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000, 279:L675–L682.
Roth M, Johnson PR, Rudiger JJ, et al.: Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002, 360:1293–1299.
Barnes PJ: Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002, 19:182–191.
Currie GP, Stenback S, Lipworth BJ: Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol 2003, 56:11–17.
Cho SH, Hartleroad JY, Oh CK: (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001, 124:478–484.
Leff AR, Herrnreiter A, Naclerio RM, et al.: Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther 1997, 10:97–104.
Volcheck GW, Kelkar P, Bartemes KR, et al.: Effects of (R)- and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5. Clin Exp Allergy 2005, 35:1341–1346.
Baramki D, Koester J, Anderson AJ, Borish L: Modulation of T-cell function by (R)- and (S)-isomers of albuterol: antiinflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002, 109:449–454.
Milligan G, Bond RA: Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 1997, 18:468–474.
Chidiac P, Hebert TE, Valiquette M, et al.: Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 1994, 45:490–499.
Elias JA, Wu Y, Zheng T, Panettieri R: Cytokine- and virus-stimulated airway smooth muscle cells produce IL-11 and other IL-6-type cytokines. Am J Physiol 1997, 273:L648–L655.
Saunders MA, Mitchell JA, Seldon PM, et al.: Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br J Pharmacol 1997, 120:545–546.
Panettieri RA Jr: Airway smooth muscle: immunomodulatory cells that modulate airway remodeling? Respir Physiol Neurobiol 2003, 137:277–293.
Endo T, Uchida Y, Nomura A, et al.: Activated eosinophils stimulate endothelin-1 release from airway epithelial cells by direct adherence via adhesion molecules. Pulm Pharmacol Ther 1997, 10:81–87.
Hallsworth MP, Soh CP, Twort CH, et al.: Cultured human airway smooth muscle cells stimulated by interleukin-1beta enhance eosinophil survival. Am J Respir Cell Mol Biol 1998, 19:910–919.
Ameredes BT, Calhoun WJ: Modulation of GM-CSF release by enantiomers of beta agonists in human airway smooth muscle. J Allergy Clin Immunol 2005, 116:65–72.
Hallsworth MP, Twort CH, Lee TH, Hirst SJ: Beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 2001, 132:729–741.
Tomlinson PR, Wilson JW, Stewart AG: Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem Pharmacol 1995, 49:1809–1819.
Ibe BO, Abdallah MF, Raj JU: Mechanisms by which S-albuterol induces human bronchial smooth muscle cell proliferation. Int Arch Allergy Immunol 2008, 146:321–333.
Ferrada MA, Gordon EL, Jen KY, et al.: (R)-albuterol decreases immune responses: role of activated T cells. Respir Res 2008, 9:3.
Auais A, Wedde-Beer K, Piedimonte G: Anti-inflammatory effect of albuterol enantiomers during respiratory syncytial virus infection in rats. Pediatr Pulmonol 2005, 40:228–234.
Perrin-Fayolle M, Blum PS, Morley J, et al.: Differential responses of asthmatic airways to enantiomers of albuterol. Implications for clinical treatment of asthma. Clin Rev Allergy Immunol 1996, 14:139–147.
Cockcroft DW, Swystun VA: Effect of single doses of Ssalbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997, 52:845–848.
Cockcroft DW, Davis BE, Swystun VA, Marciniuk DD: Tolerance to the bronchoprotective effect of beta2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999, 103:1049–1053.
Ramsay CM, Cowan J, Flannery E, et al.: Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol 1999, 55:353–359.
Sjosward KN, Hmani M, Davidsson A, et al.: Single-isomer R-salbutamol is not superior to racemate regarding protection for bronchial hyperresponsiveness. Respir Med 2004, 98:990–999.
Jacobson GA, Chong FV, Wood-Baker R: (R,S)-salbutamol plasma concentrations in severe asthma. J Clin Pharm Ther 2003, 28:235–238.
Nelson HS, Bensch G, Pleskow WW, et al.: Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998, 102:943–952.
Ahrens R, Weinberger M: Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001, 108:681–684.
Pleskow WW, Nelson HS, Schaefer K, et al.: Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004, 25:429–436.
Lotvall J, Palmqvist M, Arvidsson P, et al.: The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001, 108:726–731.
Gawchik SM, Saccar CL, Noonan M, et al.: The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999, 103:615–621.
Milgrom H, Skoner DP, Bensch G, et al.: Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001, 108:938–945.
Carl JC, Myers TR, Kirchner HL, Kercsmar CM: Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003, 143:731–736.
Nowak R, Emerman C, Hanrahan JP, et al.: A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006, 24:259–267.
Hardasmalani MD, DeBari V, Bithoney WG, Gold N: Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005, 21:415–419.
Ralston ME, Euwema MS, Knecht KR, et al.: Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005, 29:29–35.
Qureshi F, Zaritsky A, Welch C, et al.: Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005, 46:29–36.
Quinn C: The cost effectiveness of levalbuterol versus racemic albuterol. Am J Manag Care 2004, 10:S153–S157.
Pesola GR, Coelho Da’Costa V: Albuterol or levalbuterol for the treatment of asthma. Internet J Asthma Allergy Immunol 2004, 3. Available at http://www.ispub.com.
Pikarsky RS, Acevedo RA: Clinical and economic impact resulting from a hospitalwide conversion from racemic albuterol to levalbuterol. Chest 2002, 122:146S.
Pikarsky RS, Acevedo RA, Roman C, Farrell T: Comparison of rates of breakthrough treatments during a conversion from racemic albuterol to levalbuterol. Chest 2002, 122:125S.
Donohue JF, Hanania NA, Ciubotaru RL, et al.: Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther 2008, 30:989–1002.
Berger WE, Ames DE, Harrison D: A patient satisfaction survey comparing levalbuterol with racemic albuterol in children. Allergy Asthma Proc 2004, 25:437–444.
Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469–478.
Skrepnek GH, Skrepnek SV: Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care 2004, 10:S129–S138.
Cripps A, Riebe M, Schulze M, Woodhouse R: Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000, 94(Suppl B):S3–S9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ameredes, B.T., Calhoun, W.J. Levalbuterol versus albuterol. Curr Allergy Asthma Rep 9, 401–409 (2009). https://doi.org/10.1007/s11882-009-0058-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11882-009-0058-6